ATRYN Drug Profile

Summary for Tradename: ATRYN

High Confidence Patents:	0
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ATRYN Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ATRYN Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for ATRYN Derived from Patent Text Search

No patents found based on company disclosures

ATRYN Market Analysis and Financial Projection

Market Dynamics and Financial Trajectory for ATRYN

Introduction to ATRYN

ATryn, developed by rEVO Biologics, is a recombinant antithrombin III (ATIII) used for the treatment of hereditary antithrombin deficiency. This condition can lead to an increased risk of thrombosis and bleeding, particularly during surgical procedures or in cases of severe burns, nephrotic syndrome, and liver failure[1][4].

Market Size and Growth

The global antithrombin market was valued at USD 490.4 million in 2018 and is projected to reach USD 1,028.7 million by the end of 2032, exhibiting a CAGR of 5.5% during the forecast period (2018-2032)[1]. This growth is driven by the increasing prevalence of antithrombin deficiency and the rising incidence of bleeding during surgical procedures.

Regional Analysis

Asia Pacific is expected to emerge as the fastest-growing region in the antithrombin market, accounting for USD 179.7 million in 2018. The region's growth is attributed to the growing prevalence of congenital antithrombin III deficiency and increasing demand for reducing surgical mortality rates[1].

Competitive Landscape

The antithrombin market is dominated by key players such as Shire, CSL Behring, and Grifols. These companies have significant market shares due to their robust product portfolios and strong market presence[1].

Product Segmentation

The market is segmented based on the source of antithrombin:

• Human Antithrombin: This segment is expected to dominate the market due to its proven clinical efficacy.
• Goat Milk Antithrombin: This segment is likely to be the fastest-growing segment during the forecast period, driven by its clinical efficacy[1].

Therapeutic Applications

The therapeutics application segment accounted for a market share of 95.7% in 2018. Antithrombin is extensively used in surgical procedures to prevent blood clotting, making it a crucial component in anticoagulation therapy[1].

Regulatory Environment

The introduction of new antithrombin products with different indications is expected to fuel market growth. However, increasing regulations on animal testing have impeded the development of new drugs, thereby restraining market growth[4].

Financial Performance of rEVO Biologics

While specific financial data for rEVO Biologics is not provided in the sources, the overall market dynamics indicate a positive trajectory for antithrombin products. The introduction of new therapies like Fitusiran (ALN-AT3) and ATryn Antithrombin (Recombinant) suggests a strong pipeline of biologic drugs, which is expected to drive market expansion[4].

Key Takeaways

1. Market Size: The global antithrombin market is projected to reach USD 1,028.7 million by 2032.
2. Growth Drivers: Increasing prevalence of antithrombin deficiency and rising incidence of bleeding during surgical procedures.
3. Regional Growth: Asia Pacific is expected to be the fastest-growing region.
4. Competitive Landscape: Shire, CSL Behring, and Grifols dominate the market.
5. Product Segmentation: Human antithrombin is expected to dominate, while goat milk antithrombin is the fastest-growing segment.

FAQs

1. What is the current market size of the antithrombin market?

   • The global antithrombin market was valued at USD 490.4 million in 2018[1].

2. What is driving the growth of the antithrombin market?

   • The growth is driven by the increasing prevalence of antithrombin deficiency and the rising incidence of bleeding during surgical procedures[1].

3. Which region is expected to be the fastest-growing in the antithrombin market?

   • Asia Pacific is expected to emerge as the fastest-growing region[1].

4. Who are the key players in the antithrombin market?

   • Shire, CSL Behring, and Grifols are among the key players in the antithrombin market[1].

5. What are the different types of antithrombin products available in the market?

   • The market is segmented based on the source of antithrombin: human antithrombin and goat milk antithrombin[1].

References

1. Fortune Business Insights - Antithrombin Market Size, Share, Trends & Growth | Global Report.
2. Stock Titan - Atrion Reports Fourth Quarter And Full Year 2023 Results.
3. Biospace - Biologics Market Size to Reach USD 699.5 Billion by 2032, Impelled by Emergence of Advanced Drug Delivery Systems.
4. Coherent Market Insights - Antithrombin Market - Share, Size and Industry Analysis.